MediciNova Appoints David O'Toole CPA to its Board of Directors

MediciNova Appoints David O'Toole CPA to its Board of Directors

SAN DIEGO, April 10, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a
biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and
the Jasdaq Market of the Osaka Securities Exchange (Code Number:4875), today
announced the appointment of Mr. David O'Toole CPA to its Board of Directors.

"We are extremely pleased and fortunate to add an individual with such strong
financial and international experience in our industry to our Board of
Directors," said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive
Officer of MediciNova, Inc. "We believe he will be a great asset to the
company and its stockholders."

Mr. O'Toole complements the MediciNova Board with over 25 years of experience
providing finance, consulting and international tax services to global
companies. His international experience includes assignments in Tokyo, Japan
and Paris, France. Mr. O'Toole is currently Chief Financial Officer at
Response Genetics. Previously, he was Chief Financial Officer at Abraxis
Bioscience and Partner at Deloitte & Touche. Mr. O'Toole started his career at
Arthur Anderson & Co. after graduating with a BS in Accounting from the
University of Arizona.

About MediciNova

MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet need with a commercial focus on the U.S.
market.Through strategic alliances primarily with Japanese pharmaceutical
companies, MediciNova holds rights to a diversified portfolio of clinical and
preclinical product candidates, each of which MediciNova believes has a
well-characterized and differentiated therapeutic profile, attractive
commercial potential, and patent coverage of commercially adequate
scope.MediciNova's pipeline includes six clinical-stage compounds for the
treatment of acute exacerbations of asthma, chronic obstructive pulmonary
disease exacerbations, multiple sclerosis and other neurologic conditions,
asthma, interstitial cystitis, solid tumor cancers, generalized anxiety
disorder, preterm labor and urinary incontinence and two preclinical-stage
compounds for the treatment of thrombotic disorders.MediciNova's current
strategy is to focus on its two prioritized product candidates, MN-221, for
the treatment of acute exacerbations of asthma and chronic obstructive
pulmonary disease exacerbations, and ibudilast (MN-166).MN-221 is involved in
clinical trials under U.S. INDs. MN-166 is involved in clinical trials under
Investigator INDs.MediciNova is engaged in strategic partnering discussions
to support further development of the MN-221 and ibudilast programs.
Additionally, MediciNova will seek to monetize opportunistically its other
pipeline candidates.For more information on MediciNova, Inc., please visit

The MediciNova, Inc. logo is available at

Statements in this press release that are not historical in nature constitute
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, without limitation, statements regarding our progress and
expectations on future progress in the development of our drug candidates,
expected timing of clinical trial results and any implication as to the
results of our development, partnering and funding efforts or that the company
will have the ability to execute on its priorities. These forward-looking
statements may be preceded by, followed by or otherwise include the words
"believes," "expects," "anticipates," "intends," "estimates," "projects,"
"can," "could," "may," "will," "would," or similar expressions. These
forward-looking statements involve a number of risks and uncertainties that
may cause actual results or events to differ materially from those expressed
or implied by such forward-looking statements. Factors that may cause actual
results or events to differ materially from those expressed or implied by
these forward-looking statements, include, but are not limited to, risks and
uncertainties inherent in clinical trials including the unknown outcome of the
Phase 2 trial of MN-221 for the treatment of acute exacerbations of asthma,
product development and commercialization risks, the uncertainty of whether
the results of clinical trials will be predictive of results in later stages
of product development, the risk of delays or failure to obtain or maintain
regulatory approval, risks regarding intellectual property rights in product
candidates and the ability to defend and enforce such intellectual property
rights, the risk of failure of the third parties upon whom MediciNova relies
to conduct its clinical trials and manufacture its product candidates to
perform as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical trials or
significant issues regarding the adequacy of clinical trial designs or the
execution of clinical trials and the timing, cost and design of future
clinical trials and research activities, the timing of expected filings with
the regulatory authorities, risks relating to the completion of the joint
venture in China, MediciNova's collaborations with third parties, the
availability of funds to complete product development plans and MediciNova's
ability to raise sufficient capital when needed, and the other risks and
uncertainties described in MediciNova's filings with the Securities and
Exchange Commission, including its annual report on Form 10-K for the year
ended December 31, 2011 and its subsequent periodic reports on Forms 10-Q and
8-K. Undue reliance should not be placed on these forward-looking statements,
which speak only as of the date hereof. MediciNova disclaims any intent or
obligation to revise or update these forward-looking statements.

CONTACT: Mark Johnson
         Investor Relations
         MediciNova, Inc.
         (858) 373-1500

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.